vor 4 Jahren

DGAP-Adhoc: FYB201, Formycon's biosimilar for Lucentis® (ranibizumab), receives CHMP recommendation from EMA

DGAP-Ad-hoc: Formycon AG / Key word(s): Regulatory Approval/Interim Report
FYB201, Formycon's biosimilar for Lucentis® (ranibizumab), receives CHMP recommendation from EMA

24-Jun-2022 / 14:26 CET/CEST
Disclosure of an inside information acc.

Quelle: Börse Online RSS Feed

There are people out there who still trust government currency.vor 8 Stunden
When You Control Your Bitcoin, You’re Responsible for It Too.vor 8 Stunden
Brazil's largest crypto exchange, Mercado Bitcoin, suspends deposits and withdrawals after reportedly being hacked for over $40 million.vor 8 Stunden
Found something weird on my uncle’s old mining laptop from 2010. Has anyone ever heard of “Old Diff” the tortoise? [LONG]vor 8 Stunden
Bitcoin Suisse CEO: Switzerland has lost interest in cryptocurrenciesvor 9 Stunden
The Bitcoin Cash Podcast #193: BLAZE Registration & Mina Upgrade feat. Elliot Pricevor 10 Stunden
Who controls the private keys of governments' Bitcoin wallets?vor 10 Stunden
The $6.3B Question: Is Binance Running on Fractional Reserves Like FTX, and Will It Take Mass Withdrawals to Expose It?vor 14 Stunden
Infernet Protocol — We're doing to AI what Bitcoin did to moneyvor 14 Stunden
somehow, it's never enough.vor 16 Stunden

DGAP-Adhoc: FYB201, Formycon's biosimilar for Lucentis&#174; (ranibizumab), receives CHMP recommendation from EMA

DGAP-Adhoc: FYB201, Formycon's biosimilar for Lucentis® (ranibizumab), receives CHMP recommendation from EMA